520-215 AfFIRM A Phase 2 Trial of Filanesib in Relapsed/Refractory MM
Research type
Research Study
Full title
A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma
IRAS ID
156877
Contact name
Martin Kaiser
Contact email
Sponsor organisation
Array BioPharma Inc.
Eudract number
2014-001051-23
Research summary
An unmet medical need exists for patients with multiple myeloma whose disease has progressed despite treatment with various different therapies.
This need may be addressed with new drugs such as Filanesib due to the way it works.
Cancer cells contain 2 different types of proteins. One of which help the cells to survive and one of which allows them to die. When these proteins are well balanced within the cancer cells it allows the disease to continue to progress.
Filanesib works by binding to and suppressing the proteins in the cancer cells which help them to survive meaning that only the proteins that allow the cancer cells to die will remain present.
To be eligible to participate in the study patients must be over 18 years old and have a confirmed diagnosis of multiple myeloma for which they must have received 2 prior types of treatment.
The study will consist of a 4 week screening phase followed by several 28 cycles of treatment for patients who pass the screening phase.
Study assessments will include: Physical examinations, blood and urine tests, bone marrow aspirate or biopsy and radiological scans.REC name
London - West London & GTAC Research Ethics Committee
REC reference
14/LO/1444
Date of REC Opinion
20 Oct 2014
REC opinion
Further Information Favourable Opinion